Crown Princess and Prince Daniel visited Idogen
On Thursday, 30 January, the Crown Princess and Prince Daniel visited Idogen to hear about our ground-breaking research into tolerogenic cell therapies. The company described the possibilities of reprogramming cells in seriously ill patients whose immune systems have become their enemy – a technique with the potential to help many people in the future. During their visit, there were some exciting discussions about a range of topics, including Idogen’s IDO T development project, which is being developed to improve the odds of success and to help patients before undergoing a living-donor transplant.
In Idogen’s development lab, the Crown Princess Couple were able to see how our researchers develop our tolerogenic cell therapy in real time – from the starting material, which is cells from patients, to the completed and reprogrammed tolerogenic dendritic cells. The aim of this development is that these reprogrammed cells will be returned to the patient, where they will help the body’s immune system to accept, for example, a new organ.
“It was an inspirational day for all us here at Idogen. The discussions were very rewarding and we appreciate the Crown Princess Couple’s involvement in Swedish research, innovation and business development,” says Anders Karlsson, CEO of Idogen.
For additional information, please contact:
Anders Karlsson, CEO Idogen AB
Tel: +46 (0)709 18 00 10
E-mail: anders.karlsson@idogen.com
Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. Idogen’s most advanced product candidate IDO 8 is designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII (factor VIII). The company´s second project IDO T is developed to prevent kidney transplant rejection. In a third project, IDO AID, Idogen focuses on the treatment of autoimmune diseases. The treatment is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The fact that a short treatment has the potential to yield a long-lasting effect is another great advantage. For more information, visit www.idogen.com
Tags:
